Page 51 - Success Story
P. 51
BIRAC Success Stories | 2016 Virchow Biotech
Key Highlights
* Launched in India in year 2014.
Breakthrough * Reduced dependence on imports and
lower treatment costs.
• Developed RASBURICASE (Recombinant * More than 15000 units already sold.
Urate oxidase) a biosimilar useful in * Employment to ~ 50 professionals/
treating conditions associated with support staff.
initial management for plasma uric
acid levels in pediatric and adult cancer
patients.
• First biosimilar product approved in
India.
• Cost effective agent for tumor lysis
syndrome.
BIRAC’s Support
Support from BIRAC helped in
developing the technology for the
Urate Oxidase production while also
creating a platform to develop other
biosimilar products. Due to BIRAC
funding, the project also received
positive response from the medical
doctors during the Urate oxidase
clinical trials.
51
